B. Weynand

Combination of the parent analogue of Remdesivir (GS-441524) and Molnupiravir results in a markedly potent antiviral effect in SARS-CoV-2 infected Syrian hamsters

This study shows that combining GS-441524 and molnupiravir significantly reduces SARS-CoV-2 viral load in infected Syrian hamsters.

Nirmatrelvir-resistant SARS-CoV-2 is efficiently transmitted in Syrian hamsters

This study shows that nirmatrelvir-resistant SARS-CoV-2 variants replicate and transmit efficiently in Syrian hamsters, highlighting the need for combination therapies to prevent resistance spread.

A SCID mouse model to evaluate the efficacy of antivirals against SARS-CoV-2 infection

This paper establishes a SCID mouse model infected with the SARS-CoV-2 beta B.1.351 variant to evaluate antiviral efficacy, showing significant reduction in viral load with Molnupiravir and Nirmatrelvir.

ACE2 engagement exposes the fusion peptide to pan-coronavirus neutralizing antibodies

The paper identifies monoclonal antibodies that neutralize multiple coronaviruses by targeting the fusion peptide, which becomes exposed upon ACE2 engagement.

Ivermectin does not protect against SARS-CoV-2 infection in the Syrian hamster model

This study shows that Ivermectin does not reduce SARS-CoV-2 lung viral load or improve lung pathology in Syrian hamsters and does not enhance Molnupiravir's effect.

The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters

This study shows that the omicron SARS-CoV-2 variant infects Syrian hamsters with significantly lower viral loads in the lungs compared to the D614G strain, with no detectable infectious virus.

Updated vaccine protects from infection with SARS-CoV-2 variants, prevents transmission and is immunogenic against Omicron in hamsters

This study shows an updated vaccine candidate provides full protection against multiple SARS-CoV-2 variants, prevents transmission, and induces neutralizing antibodies against Omicron in hamsters.

The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern

PF-07321332, an oral protease inhibitor, effectively protects Syrian hamsters against SARS-CoV-2 variants of concern, including beta and delta, by preventing infection and transmission.

Comparative infectivity and pathogenesis of emerging SARS-CoV-2 variants in Syrian hamsters

This study compares the infectivity and pathogenicity of SARS-CoV-2 variants B.1.1.7 and B.1.351 to early 2020 strains in Syrian hamsters, finding similar disease outcomes but stronger proinflammatory cytokine elevation in B.1.1.7 infections.

Nelfinavir markedly improves lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect

Nelfinavir reduces SARS-CoV-2-induced lung pathology in Syrian hamsters without affecting viral RNA or infectious titers.

The combined treatment of Molnupiravir and Favipiravir results in a marked potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model

This study shows that combining Molnupiravir and Favipiravir significantly enhances antiviral efficacy against SARS-CoV-2 in hamsters, reducing viral titers by 4.5 log10 and eliminating detectable virus in 60% of treated animals.

Antiviral treatment of SARS-CoV-2-infected hamsters reveals a weak effect of favipiravir and a complete lack of effect for hydroxychloroquine

This study evaluates the antiviral effects of favipiravir and hydroxychloroquine in SARS-CoV-2-infected hamsters, finding limited efficacy for both drugs.

A Pan-Cancer Blueprint of the Heterogeneous Tumour Microenvironment Revealed by Single-Cell Profiling

This study profiles single cells from multiple cancer types to create a pan-cancer blueprint of stromal cell heterogeneity, identifying shared and unique cell populations and their characteristics.